Medicenna Therapeutics Corp.
MDNAF
$0.7151
-$0.0289-3.88%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.22% | 43.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.74% | 37.25% | |||
| Operating Income | 9.74% | -37.25% | |||
| Income Before Tax | -21.46% | -14.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.46% | -14.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.46% | -14.87% | |||
| EBIT | 9.74% | -37.25% | |||
| EBITDA | 9.70% | -37.27% | |||
| EPS Basic | -19.65% | -9.97% | |||
| Normalized Basic EPS | -19.76% | -9.73% | |||
| EPS Diluted | -19.65% | -9.97% | |||
| Normalized Diluted EPS | -19.76% | -9.73% | |||
| Average Basic Shares Outstanding | 1.52% | 4.37% | |||
| Average Diluted Shares Outstanding | 1.52% | 4.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
